Clavis Pharma announces encouraging interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with AML
Biomarker analysis suggests hENT1 levels may identify patients for whom elacytarabine could be an effective treatment
22-Aug-2011 -
Clavis Pharma ASA announces encouraging interim efficacy data from its Phase II clinical trial with elacytarabine in combination with idarubicin in patients with acute myeloid lymphoma (AML) who have failed cytarabine (ara-C)-containing first-course chemotherapy. Elacytarabine is a novel, ...
acute myeloid lymphoma, AML
cancer
Clavis Pharma
+1